Cargando…

Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment

Introduction: Vascular cognitive impairment (VCI) is one of the most common types of dementia. Naoxin'an capsule (NXA), a traditional Chinese medicine compound, has been used to treat VCI for a long time in the clinic. Previous studies proved that the NXA capsules could ameliorate the cerebral...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hui, Dang, Mingxi, Chen, Kewei, Shang, Huajie, Wang, Bolong, Zhao, Shaokun, Li, Xin, Zhang, Zhanjun, Zhang, Junying, Chen, Yaojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113453/
https://www.ncbi.nlm.nih.gov/pubmed/37089924
http://dx.doi.org/10.3389/fphar.2023.1129125
_version_ 1785027840535691264
author Lu, Hui
Dang, Mingxi
Chen, Kewei
Shang, Huajie
Wang, Bolong
Zhao, Shaokun
Li, Xin
Zhang, Zhanjun
Zhang, Junying
Chen, Yaojing
author_facet Lu, Hui
Dang, Mingxi
Chen, Kewei
Shang, Huajie
Wang, Bolong
Zhao, Shaokun
Li, Xin
Zhang, Zhanjun
Zhang, Junying
Chen, Yaojing
author_sort Lu, Hui
collection PubMed
description Introduction: Vascular cognitive impairment (VCI) is one of the most common types of dementia. Naoxin'an capsule (NXA), a traditional Chinese medicine compound, has been used to treat VCI for a long time in the clinic. Previous studies proved that the NXA capsules could ameliorate the cerebral mitochondrion deficits of VCI animals. This study aimed to investigate the protectiveness of NXA on human brain structure and function in patients with VCI. Methods: In total, 100 VCI patients were enrolled in this 24-week trial and randomly divided into the NXA capsules group (n = 50) and the ginkgo biloba capsules control group (n = 50). Before and after the treatment, cognitive behavior tests and multimodal brain magnetic resonance imaging were analyzed to comprehensively evaluate the effectiveness of NXA treatment on VCI patients after 24 weeks. Results: We found that the NXA group significantly improved overall cognitive ability (Alzheimer's Disease Assessment Scale-Cognitive section, p = 0.001; Mini-Mental Status Examination, p = 0.003), memory (Rey-Osterrieth Complex Figure test, p < 0.001) and executive function (Trail Making Test-A, p = 0.024) performance after treatment compared with the control group. For brain function, the degree of centrality in the left middle frontal gyrus, right postcentral gyrus, and left supplementary motor area increased in the NXA group and decreased in the ginkgo biloba group after treatment. The fractional amplitude of low-frequency fluctuation (fALFF) of the left precentral and right superior parietal gyrus increased, and the fALFF of the right parahippocampal and left inferior temporal gyrus decreased in the NXA group after treatment. For brain structure, the gray matter density of the left postcentral gyrus increased in the NXA group after treatment, and the total volume of white matter hyperintensity showed a decreasing trend but was not statistically significant. Furthermore, the improvement effect of NXA on executive function was associated with changes in brain function. Conclusion: These findings suggest that the NXA capsules improved cognitive performance and multiregional brain function, as well as gray matter structure in the postcentral gyrus.
format Online
Article
Text
id pubmed-10113453
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101134532023-04-20 Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment Lu, Hui Dang, Mingxi Chen, Kewei Shang, Huajie Wang, Bolong Zhao, Shaokun Li, Xin Zhang, Zhanjun Zhang, Junying Chen, Yaojing Front Pharmacol Pharmacology Introduction: Vascular cognitive impairment (VCI) is one of the most common types of dementia. Naoxin'an capsule (NXA), a traditional Chinese medicine compound, has been used to treat VCI for a long time in the clinic. Previous studies proved that the NXA capsules could ameliorate the cerebral mitochondrion deficits of VCI animals. This study aimed to investigate the protectiveness of NXA on human brain structure and function in patients with VCI. Methods: In total, 100 VCI patients were enrolled in this 24-week trial and randomly divided into the NXA capsules group (n = 50) and the ginkgo biloba capsules control group (n = 50). Before and after the treatment, cognitive behavior tests and multimodal brain magnetic resonance imaging were analyzed to comprehensively evaluate the effectiveness of NXA treatment on VCI patients after 24 weeks. Results: We found that the NXA group significantly improved overall cognitive ability (Alzheimer's Disease Assessment Scale-Cognitive section, p = 0.001; Mini-Mental Status Examination, p = 0.003), memory (Rey-Osterrieth Complex Figure test, p < 0.001) and executive function (Trail Making Test-A, p = 0.024) performance after treatment compared with the control group. For brain function, the degree of centrality in the left middle frontal gyrus, right postcentral gyrus, and left supplementary motor area increased in the NXA group and decreased in the ginkgo biloba group after treatment. The fractional amplitude of low-frequency fluctuation (fALFF) of the left precentral and right superior parietal gyrus increased, and the fALFF of the right parahippocampal and left inferior temporal gyrus decreased in the NXA group after treatment. For brain structure, the gray matter density of the left postcentral gyrus increased in the NXA group after treatment, and the total volume of white matter hyperintensity showed a decreasing trend but was not statistically significant. Furthermore, the improvement effect of NXA on executive function was associated with changes in brain function. Conclusion: These findings suggest that the NXA capsules improved cognitive performance and multiregional brain function, as well as gray matter structure in the postcentral gyrus. Frontiers Media S.A. 2023-04-05 /pmc/articles/PMC10113453/ /pubmed/37089924 http://dx.doi.org/10.3389/fphar.2023.1129125 Text en Copyright © 2023 Lu, Dang, Chen, Shang, Wang, Zhao, Li, Zhang, Zhang and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lu, Hui
Dang, Mingxi
Chen, Kewei
Shang, Huajie
Wang, Bolong
Zhao, Shaokun
Li, Xin
Zhang, Zhanjun
Zhang, Junying
Chen, Yaojing
Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
title Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
title_full Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
title_fullStr Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
title_full_unstemmed Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
title_short Naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
title_sort naoxin’an capsules protect brain function and structure in patients with vascular cognitive impairment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113453/
https://www.ncbi.nlm.nih.gov/pubmed/37089924
http://dx.doi.org/10.3389/fphar.2023.1129125
work_keys_str_mv AT luhui naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT dangmingxi naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT chenkewei naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT shanghuajie naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT wangbolong naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT zhaoshaokun naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT lixin naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT zhangzhanjun naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT zhangjunying naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment
AT chenyaojing naoxinancapsulesprotectbrainfunctionandstructureinpatientswithvascularcognitiveimpairment